Thailand's New Cannabis & Hemp Extract Rules: The Four Permitted Uses Explained

Thailand drew a hard line through cannabis and hemp commerce in March 2026 and made it operational a month later. The Ministerial Regulation on permission to produce, import, export, sell or possess Category 5 narcotics, specifically cannabis or hemp plant extracts, B.E. 2569 (2026) — published in the Royal Gazette on 26 March 2026, effective 26 April 2026 — settles a question that had been ambiguous since the 2022 decriminalization: what happens to cannabis and hemp once you extract concentrated THC content from it?

The answer is now unambiguous: extracts containing more than 0.2% THC by weight are Category 5 narcotics, and their commercial use is limited to four specifically permitted purposes.

This is the operator-level and consumer-level breakdown.

The Regulation at a Glance

• Full name: Ministerial Regulation on permission to produce, import, export, sell or possess Category 5 narcotics, specifically cannabis or hemp plant extracts, B.E. 2569 (2026)
• Thai name: กฎกระทรวง การอนุญาตผลิต นำเข้า ส่งออก จำหน่าย หรือมีไว้ในครอบครองซึ่งยาเสพติดให้โทษในประเภท 5 เฉพาะสารสกัดจากพืชกัญชาหรือกัญชง พ.ศ.2569
• Royal Gazette publication: 26 March 2026
• Effective date: 26 April 2026 (30 days after publication)
• Signed by: Public Health Minister Pattana Promphat
• Threshold: More than 0.2% THC by weight = Category 5 narcotic
• Old licence cliff: 31 December 2026

The 0.2% THC Threshold

The threshold is not new — it was already the line separating regulated extracts from unrestricted hemp products under earlier rules. What changed in 2026 is the closure of ambiguity around what happens above the line.

• At or below 0.2% THC: Not a narcotic. CBD oils, hemp-derived foods and cosmetics, hemp seed oil, and industrial hemp products continue under the general hemp framework. No PT 33 prescription required for retail. No production/import licence under this regulation.
• Above 0.2% THC: Category 5 narcotic. Production, import, export, sale, and possession all require a licence under the 2569 framework, and that licence is only available for one of four permitted purposes.

For consumers buying CBD oils or hemp products, this means very little changes. For extractors, formulators, and pharmaceutical operators, it changes the structure of the licensing path entirely.

The Four Permitted Uses

The regulation defines exactly four purposes for which a licence to handle cannabis or hemp extracts above the 0.2% threshold may be issued. Verbatim from the regulation:

1. Official Use in Preventing and Suppressing Narcotics Offences

เพื่อประโยชน์ของทางราชการในการป้องกันและปราบปรามการกระทำความผิดเกี่ยวกับยาเสพติด

This covers official government functions: forensic laboratories, narcotics enforcement testing, evidence handling, and similar activities by state agencies. It is not a commercial channel.

2. Medical Purposes

เพื่อประโยชน์ในทางการแพทย์

Pharmaceutical-grade cannabis extracts for prescription medical use. This is the primary commercial channel under the new regulation. Hospitals, the GPO (Government Pharmaceutical Organization), licensed pharmaceutical manufacturers, and clinical practitioners with appropriate qualifying credentials operate within this category.

3. Analysis, Education, or Medical/Scientific Research

เพื่อการวิเคราะห์ การศึกษา หรือการศึกษาวิจัยทางการแพทย์หรือวิทยาศาสตร์

Research institutions, universities, accredited testing laboratories, and similar entities engaged in non-commercial analysis or scientific research. Includes Certificate of Analysis (COA) testing for batch quality verification.

4. Industrial Purposes

เพื่อประโยชน์ในทางอุตสาหกรรม

Industrial applications such as material science research, formulation development, and adjacent uses where the extract is an input rather than a consumer product. This is the narrowest category in practice — industrial uses for extracts above 0.2% THC are limited.

Anything outside these four uses is not a legal pathway under the new regulation. Recreational extracts, consumer-facing high-THC products outside the medical channel, and undefined “wellness” categories are excluded.

Who Can Apply

The regulation restricts applicants to:

• Thai juristic persons that are not classified as “foreigners” under the Foreign Business Act B.E. 2542
• Government agencies and state enterprises
• The Thai Red Cross Society

Foreign-owned businesses are explicitly excluded from producing, importing, or exporting cannabis or hemp extracts above the 0.2% THC threshold. This is a structural constraint, not a procedural hurdle — there is no “foreign ownership cap” workaround in this regulation. International cannabis companies seeking participation must either:

1. Operate through a fully Thai-owned subsidiary (not a 49% foreign / 51% Thai joint venture)
2. License technology and IP to a qualified Thai operator
3. Limit involvement to advisory and service relationships
4. Focus on the under-0.2% THC market, which remains open to broader business structures

The 31 December 2026 Cliff

Licences issued under the previous ministerial regulations from 2020 and 2021 remain valid only until 31 December 2026. This is the most operationally urgent date in the regulation.

After 1 January 2027:

• Every operator producing, importing, exporting, selling, or possessing cannabis/hemp extracts above 0.2% THC must hold a licence under the 2569 framework
• Operators without a 2569 licence on 1 January 2027 are operating without authorization
• The transition window is the eight months from 1 May 2026 through 31 December 2026

Operators should:

• Audit their current licence portfolio immediately
• Identify which existing licences fall under the pre-2569 framework
• Submit fresh applications under the new framework with sufficient lead time for review
• Have a contingency plan for any gap between old-licence expiry and new-licence approval

What This Means for CBD Brands and Hemp Operators

The vast majority of CBD products sold in Thailand are at or below the 0.2% THC threshold. For these products:

• Retail sales continue under existing FDA registration paths (food, supplement, cosmetic)
• No PT 33 prescription required for consumers
• No 2569 licence required for the brand
• Foreign ownership is not restricted at the under-0.2% level (subject to standard Foreign Business Act rules)

The regulation matters for CBD brands in two specific situations:

1. Full-spectrum products where THC content varies across batches and can occasionally exceed 0.2%. Batch testing and certificates of analysis become more important — a single hot batch can pull the product into narcotics classification.
2. High-CBD extract production where the production process itself temporarily concentrates THC above the threshold before dilution. The intermediate extract is a narcotic under the regulation even if the final product is not.

What This Means for Pharmaceutical and Medical Operators

The four-permitted-uses framework is now the operating channel for any extract-based medical cannabis product in Thailand. Practical consequences:

• Hospital pharmaceutical extracts (the GPO formulations, hospital-compounded preparations) operate under criterion 2 (medical)
• Clinical trial supplies operate under criterion 3 (research)
• Reference standards and analytical samples operate under criterion 3
• Pharmaceutical-grade extract production requires a 2569 licence and Thai juristic-person status
• PT 33 prescriptions continue to be the patient-facing access mechanism — the 2569 regulation is upstream of the prescription, not a substitute for it

What This Means for Research Institutions

Universities, state research institutes, the Thai Red Cross, and other research entities have the clearest path under the new regulation. Criterion 3 (analysis, education, research) was designed for these actors. Research-only applications generally proceed under simplified pathways relative to commercial applications.

For private-sector research collaborations with universities, the licence holder is the Thai institution. Commercial partners contribute funding, equipment, and IP but do not hold the licence themselves unless they independently qualify under the Thai-juristic-person rules.

How This Sits Alongside the Cannabis-Flower Regulation

This extract regulation is one of two ministerial regulations that took effect in April 2026. The other one — Ministerial Regulation (No. 2) B.E. 2569 published 30 April 2026 — governs cannabis-flower commerce under the controlled-herbs framework. The two regulations operate on parallel tracks:

Operators handling both flower and extracts (most pharmaceutical-grade cannabis producers) need licences under both frameworks.

For the flower-side compliance walkthrough, see our Ministerial Regulation No. 2 B.E. 2569 guide. For the consolidated picture, see our May 2026 law update.

Penalty Framework

The 2569 regulation itself is a licensing instrument and does not state penalty amounts. Penalties for unlicensed activity flow from the underlying Narcotics Code, which classifies cannabis and hemp extracts above 0.2% THC as Category 5 narcotics. Unlicensed production, import, export, sale, or possession of Category 5 narcotics carries serious criminal penalties including imprisonment.

Operators should not rely on the absence of penalty text in the regulation itself — the penalties are statutory and substantial.

Compliance Checklist for Extract Operators

If you handle cannabis or hemp extracts above 0.2% THC:

• Identify which of the four permitted uses your operation falls under
• Confirm Thai juristic-person status (or fall under the government / Thai Red Cross exception)
• Audit existing licences for expiry date and underlying regulation framework
• Plan submission of a fresh 2569-framework application with sufficient lead time before 31 December 2026
• Implement batch THC testing to prevent unintended border crossings of the 0.2% threshold
• Document storage, handling, and chain-of-custody to narcotics-level standards
• Engage Thai counsel familiar with both the Narcotics Code and ministerial-regulation practice

What to Watch in the Next Eight Months

1. Approval throughput. With every pre-2569 licence holder needing to refile by 31 December 2026, the licensing authority faces a volume spike. Watch for clarifying notifications about prioritization and review timelines.
2. Cannabis & Hemp Act passage. The Cannabis and Hemp Act draft is in public consultation through 21 May 2026. If passed, the act could supersede portions of the 2569 ministerial framework with statutory provisions, particularly around penalty schedules and the foreign-ownership question. See our consultation tracker for ongoing updates.
3. Border enforcement. Import and export of cannabis and hemp extracts have historically been a customs enforcement focus. Expect tighter screening at major ports and international airports.

Resources

• Cannabis Laws Thailand 2026 — pillar guide
• Ministerial Regulation No. 2 B.E. 2569 compliance guide
• Cannabis and Hemp Act consultation tracker
• Cannabis business licence guide